van Eijs, Mick J. M. http://orcid.org/0000-0002-9763-6704
Verheijden, Rik J. http://orcid.org/0000-0003-1966-1063
van der Wees, Stefanie A.
Nierkens, Stefan http://orcid.org/0000-0003-3406-817X
van Lindert, Anne S. R. http://orcid.org/0000-0002-4072-2441
Suijkerbuijk, Karijn P. M. http://orcid.org/0000-0003-3604-5430
van Wijk, Femke http://orcid.org/0000-0001-8343-1356
Meyaard, Linde
Kuball, Jürgen H. E.
Oldenburg, Bas
Leusen, Jeanette H. W.
,
Funding for this research was provided by:
Bristol-Myers Squibb (CA209-6JY, CA209-6JY, CA209-6JY)
Article History
Received: 31 March 2023
Accepted: 3 September 2023
First Online: 4 October 2023
Declarations
:
: KPMS has advisory relationships with Bristol Myers Squibb, Novartis, MSD, Pierre Fabre, AbbVie, received honoraria from Novartis, MSD and Roche and received research funding from BMS, Philips and TigaTx. FW has advisory relationships with Janssen and Takeda, and received research funding from Takeda, Galapagos, BMS, Sanofi, and Leo Pharma.
: This study was approved by the University Medical Center Utrecht biobank committee (TCbio 18–123).
: All participants provided written informed consent in line with the Declaration of Helsinki.